TScan Therapeutics, Inc.
TCRX
$1.08
$0.032.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 266.65% | -10.03% | -42.94% | -70.15% | -86.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 266.65% | -10.03% | -42.94% | -70.15% | -86.62% |
| Cost of Revenue | 4.84% | 22.97% | 21.84% | 23.07% | 21.78% |
| Gross Profit | 2.21% | -26.36% | -31.17% | -41.14% | -55.78% |
| SG&A Expenses | 4.30% | 18.29% | 23.22% | 24.03% | 14.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.72% | 21.94% | 22.14% | 23.28% | 20.20% |
| Operating Income | 0.75% | -24.44% | -29.25% | -36.84% | -44.26% |
| Income Before Tax | -1.78% | -28.12% | -30.99% | -35.83% | -42.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.78% | -28.12% | -30.99% | -35.83% | -42.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.78% | -28.12% | -30.99% | -35.83% | -42.91% |
| EBIT | 0.75% | -24.44% | -29.25% | -36.84% | -44.26% |
| EBITDA | -0.18% | -27.03% | -32.32% | -40.42% | -48.37% |
| EPS Basic | 14.87% | -14.51% | -15.53% | -17.97% | -3.80% |
| Normalized Basic EPS | 14.82% | -13.62% | -14.62% | -17.01% | -2.98% |
| EPS Diluted | 14.87% | -14.51% | -15.53% | -17.97% | -3.80% |
| Normalized Diluted EPS | 14.82% | -13.62% | -14.62% | -17.01% | -2.98% |
| Average Basic Shares Outstanding | 42.30% | 12.20% | 13.64% | 15.05% | 26.15% |
| Average Diluted Shares Outstanding | 42.30% | 12.20% | 13.64% | 15.05% | 26.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |